'Targeted' molecular diversity: Design and development of non-peptide antagonists for cholecystokinin and tachykinin receptors

Immunopharmacology

Volumn 33, Issue 1-3, 1996, Pages 68-72

  Horwell, David ^a   Pritchard, Martyn ^a   Raphy, Jennifer ^a   Ratcliffe, Giles ^a  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

'Targeted molecular diversity'; CCK A; CCK B; cholecystokinin; dipeptide library; NK 1; NK 2; NK 3; non peptide antagonists; subs tance P; tachykinins

Indexed keywords

4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; ALPHA METHYL N [(TRICYCLO[3.3.1.1 3,7]DEC 2 YLOXY)CARBONYL]TRYPTOPHYL DEXTRO 3 BENZYL BETA ALANINE; CAM 2291; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; CHOLECYSTOKININ RECEPTOR; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ 2 RECEPTOR ANTAGONIST; NEUROKININ 3 RECEPTOR ANTAGONIST; PD 157672; TACHYKININ RECEPTOR; TACHYKININ RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; [2 (1H INDOL 3 YLMETHYL) 1 (1 PHENYLETHYLCARBAMOYL)ETHYL]CARBAMIC ACID BENZOFURAN 2 YLMETHYL ESTER; [2 (2,3 DIFLUOROPHENYL) 1 METHYL 1 [(7 UREIDOHEPTYL)CARBAMOYL]ETHYL]CARBAMIC ACID 2 METHYL 1 PHENYLPROPYL ESTER;

BINDING AFFINITY; CHEMICAL STRUCTURE; CONFERENCE PAPER; DRUG DESIGN; DRUG SELECTIVITY; HUMAN; LIBRARY; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RECEPTOR BINDING;

EID: 0030175369     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/0162-3109(96)00058-6     Document Type: Conference Paper

References (14)

1. Boden P, Higginbottom M, Hill, DR, Horwell, DC, Hughes, J, Rees DC, Roberts E, Singh L, Suman-Chauhan N, Woodruff GN, Cholecystokinin dipeptoid antagonists: design, synthesis, and anxiolytic profile of some novel CCK-A and CCK-B selective and 'mixed' CCK-A/CCK-B antagonists. J Med Chem 1993; 36: 552-565.
2. Boden P, Eden JM, Hodgson J, Horwell DC, Howson W, Hughes J, McKnight AT, Meecham K, Pritchard MC, Raphy J, Ratcliffe GS, Suman-Chauhan N, Woodruff GN. The rational development of small molecule tachykinin NK-3 receptor selective antagonists - the utilisation of a dipeptide chemical library in drug design. BioMed Chem Lett 1994; 4: 1679-1684.
3. Boden P, Eden JM, Hodgson J, Horwell DC, Pritchard MC, Raphy J, Suman-Chauhan N. The development of a novel series of non-peptide tachykinin NK-3 receptor antagonists. BioMed Chem Lett 1995; 5: 1773-1778.
4. Boyle S, Guard S, Higginbottom M, Horwell DC, Howson W, Hughes J, McKnight A, Martin K, Pritchard MC, O'Toole J, Raphy J, Rees DC, Roberts E, Watling KJ, Woodruff GN. Rational design of high affinity tachykinin NK-1 receptor antagonists. BioMed Chem 1994a; 2: 357-370.
5. Boyle S, Guard S, Hodgson J, Horwell DC, Howson W, Hughes J, McKnight A, Martin K, Pritchard MC, Watling KJ, Woodruff, GN. Rational design of high affinity tachykinin NK-2 receptor antagonists. BioMed Chem 1994b; 2: 101-113.
6. Hayward NJ, Harding M, Lloyd SAC, McKnight A, Hughes J, Woodruff GN. The effects of CCK-B/gastrin antagonists on stimulated gastric acid secretion on the anaesthetized rat. Br J Pharmacol 1991; 104: 973-977.
7. Hellberg S, Eriksson L, Jonsson J, Lindgren F, Sjöström M, Skakerberg B, Wold S, Andrews P. Minimum analogue peptide sets (MAPS) for quantitative structure-activity relationship, Int J Pept Protein Res 1991; 37: 414-424.
8. Höcker M, Hughes J, Fölsch UR, Schmidt W. PD 135158, a CCK-gastrin receptor antagonist, stimulates rat pancreatic enzyme secretion as a CCK-A receptor agonist. Eur J Pharmacol 1993; 242: 105-108.
9. Horwell DC, Howson W, Ratcliffe GS, Rees DC. The design of a dipeptide library for screening at peptide receptor sites. BioMed Chem Lett 1993; 3: 799-802.
10. Horwell DC. The 'peptoid' approach to the design of non-peptide, small molecule agonists and antagonists of neuropeptides. In: Trends in Biotechnology. Amsterdam: Elsevier, 1995; 13: 132-134.
11. Hughes J, Boden P, Costall B, Domeney A, Kelly E, Horwell DC, Hunter JC, Pinnock RD, Woodruff GN. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci USA 1990; 87: 6728-32.
12. Schmassmann A, Garner A, Flogerzi B, Hasan MY, Sanner M, Varga L, Halter F, Cholecystokinin type B receptor antagonist PD 136450 is a partial secretory agonist in the stomach and a full agonist in the pancreas of the rat. Gut 1994; 35: 270-274.
13. Weisenfeld-Hallin Z, Xu X-J, Hughes J, Horwell DC, Hökfelt. PD 134308, a new selective CCK-B antagonist enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes. Proc Natl Acad Sci USA 1990; 87: 7, 105-9.
14. Woodruff GN, Hughes J. Cholecystokinin antagonists. Annu Rev Pharmacol Toxicol 1991; 31: 469-501.